Hamad Medical Corporation
Doha, 3050, Qatar
NCT Number: NCT04853979
The investigator hypothesis is that early implementation of early, awake prone position for patients with COVID-19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support. Escalation of respiratory support is defined as the need for respiratory support with HFNO, NIV or IV.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Doha, 3050, Qatar
The world health organization has designated the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as an ongoing pandemic and a public health emergency of international concern. The disease is estimated to be severe in 20% of patients and about 5-10% will need critical care with respiratory support. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.
Prone positioning causes a substantial improvement in oxygenation that appear to persist after the patient is returned to a supine position. It has also been shown to have a significant mortality benefit in invasively ventilated ARDS patients. Observational studies have shown improvement in oxygenation with awake prone positioning in non-intubated patients with COVID-19 pneumonia. There is no published RCTs to date. It remains unclear whether prone positioning averts invasive or non-invasive ventilation, accelerates recovery, or reduces mortality. Similarly, there is no data on presumed viral pneumonia. Future studies are needed to identify the optimal indications for, duration of pronation, and assessment of response.
Hypothesis: The investigator hypothesis is that early implementation of early, awake pronation for patients with Covid19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support. Escalation of respiratory support is defined as the need for respiratory support with HFNO, NIV or IV Research participants: Adults 18 years and older with suspected or confirmed COVID-19 presenting to HMC with hypoxemic respiratory failure (PF<200 or SpO2 less than 94% on FiO2>=0.4 or =>5 lit/min O2)
Design: This is a non-blinded randomized controlled trial. Participants will be randomized to one of two study arms:
Methods and outcomes:
Data will be analyzed for escalation of respiratory support within the first three days of the study. Escalation of respiratory support is defined as follows:
Based on previous studies of prone position in COVID-19 patients, anticipate an improvement in oxygenation and possible prevention of intubation with shorter mechanical ventilation times. Awake proning has been shown to be safe in local practice.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All adults with suspected or confirmed COVID-19 and hypoxemia respiratory failure.
Exclusion criteria
Any combination of prone or side position for 3 hours, 3 times a day for 3 days
Time frame: 30 days
To assess the potential for prone position to reduce the requirement for escalation of respiratory support.
Hamad Medical Corporation
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04427878
COVID-19 Patients
Nice, France
View Trial DetailsNCT05901337
COVID-19 Patients
Giza, Egypt
View Trial DetailsNCT05369676
COVID-19 Patients
Shenzhen, Guangdong, China
View Trial DetailsNCT05162534
COVID-19, COVID-19 Patients
Ferrara, Emilia-Romagna, Italy
View Trial Details